Eligible patients living with rare debilitating genetic disorder are one step closer to having access to first-of-its-kind treatment option
Takeda Canada Announces New OnePath® Patient Support Program
Amalgamation of Takeda Canada Inc. and Shire Pharma Canada ULC Solidifies Company’s Leadership Position in Canadian Biopharmaceutical Industry
Updated COVID-19 Healthcare Professional Letter
Self-injectable formulation of ENTYVIO® (vedolizumab) approved in Canada for the maintenance treatment of moderately to severely active ulcerative colitis
